Ionis Pharmaceuticals IONS Change in Deferred Revenue
Change in Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's change in deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's change in deferred revenue?
- Ionis Pharmaceuticals (IONS) reported change in deferred revenue of -$20.82M in Q1 2026.
- How has Ionis Pharmaceuticals's change in deferred revenue changed year-over-year?
- Ionis Pharmaceuticals's change in deferred revenue decreased by 51.8% year-over-year, from -$13.72M to -$20.82M.
- What is the long-term trend for Ionis Pharmaceuticals's change in deferred revenue?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's change in deferred revenue has grown at a -4.2% compound annual growth rate (CAGR), from -$82.83M to -$69.73M.
- What does change in deferred revenue mean?
- The net change in cash received from customers for services not yet delivered.
- How do you interpret change in deferred revenue?
- An increase suggests strong upfront billing or prepayments, while a decrease indicates the recognition of previously deferred revenue or a slowdown in new contract billings.
- How does change in deferred revenue compare across companies?
- Common in biotech and software companies with milestone-based or subscription-based revenue models.